DXCM - DexCom - Stock Price & Dividends

DexCom, Inc. is a medical device company that specializes in designing, developing, and commercializing continuous glucose monitoring (CGM) systems for people with diabetes and healthcare providers worldwide.

The company's product portfolio includes the Dexcom G6 and Dexcom G7, which are integrated CGM systems designed to help manage diabetes. These systems provide real-time glucose data, enabling users to make informed decisions about their treatment plans. Additionally, DexCom offers Dexcom Share, a remote monitoring system that allows users to share their glucose data with healthcare providers, family members, or friends, ensuring timely interventions and support.

DexCom also provides the Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices. This allows for seamless data sharing and more comprehensive diabetes management. Furthermore, the company has developed Dexcom ONE, a system designed to replace finger stick blood glucose testing for diabetes treatment decisions, providing a more convenient and accurate alternative.

In addition, DexCom has submitted the Dexcom Stelo for FDA review, which is specifically designed for people with type 2 diabetes. The company has also partnered with Verily Life Sciences LLC and Verily Ireland Limited to develop innovative blood-based or interstitial glucose monitoring products, expanding its offerings and capabilities.

DexCom markets its products directly to endocrinologists, physicians, and diabetes educators, ensuring that its solutions reach those who need them most. With a strong focus on innovation and customer needs, the company has established itself as a leader in the CGM market since its incorporation in 1999. Headquartered in San Diego, California, DexCom continues to drive progress in diabetes management and care.